Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies
Safety and efficacy of Ravulizumab for pediatric patients with thrombocytic microangiopathy following hematopoetic stem cell transplantation
Full IRB Study Title:
ALXN1210-TMA-314: A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)
IRB Study ID: 2021-018-ACH
View complete study details here.
Study Sponsor:
Alexion Pharmaceuticals, Inc.
We are currently recruiting
If you are interested in this study or have questions about your child's eligibility, please contact:
Showers Family Center for Childhood Cancer and Blood Disorders. 330-543-8730
